Doxitinib mesylate

Main purpose: To evaluate the safety and tolerability of doxitinib mesylate tablets (90-1408) in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of single/multiple administration of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To evaluate the preliminary efficacy of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To evaluate the preliminary efficacy of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with T790M mutations; To evaluate the safety of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with T790M mutations; To explore the drug metabolism profile of 90-1408 in plasma and urine.